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ABSTRACT
Background
Prostate cancer is a major public health issue, mainly because pa-
tients relapse after androgen deprivation therapy. Proteomic strate-
gies, aiming to reflect the functional activity of cells, are nowadays
among the leading approaches to tackle the challenges not only of
better diagnosis, but also of unraveling mechanistic details related
to disease etiology and progression.
Methods
We conducted here a large SILAC-based Mass Spectrometry exper-
iment to map the proteomes and phosphoproteomes of four widely
used prostate cell lines, namely PNT1A, LNCaP, DU145 and PC3,
representative of different cancerous and hormonal status.
Results
We identified more than 3000 proteins and phosphosites, from
which we quantified more than 1000 proteins and 500 phosphosites
after stringent filtering. Extensive exploration of this proteomics
and phosphoproteomics dataset allowed characterizing housekeep-
ing as well as cell-line specific proteins, phosphosites and functional
features of each cell line. In addition, by comparing the sensitive
and resistant cell lines, we identified protein and phosphosites dif-
ferentially expressed in the resistance context. Further data integra-
tion in a molecular network highlighted the differentially expressed
pathways, in particular migration and invasion, RNA splicing, DNA
damage repair response and transcription regulation.
Conclusions
Overall, this study proposes a valuable resource toward the charac-
terization of proteome and phosphoproteome of four widely used
prostate cell lines and reveals candidates to be involved in prostate
cancer progression for further experimental validation.
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Introduction
Prostate cancer (PC) is a major public health issue in in-
dustrialized countries, mainly because patients relapse by
castration-resistant disease after androgen deprivation (1, 2).
PC is associated to a panel of clinical states characterized
by tumor growth, hormonal status (castration-sensitive or
castration-resistant) and presence/absence of metastases. Af-
ter androgen deprivation therapy, the disease usually pro-
gresses to castration-resistant prostate cancer (CRPC), which
is highly aggressive and incurable, and jeopardizes the pa-
tient’s lifespan and quality of life. This progression involves
several molecular mechanisms such as ligand-independent
androgen receptor activation or adaptive upregulation of anti-
apoptotic genes (for review (3)).
Despite an existing treatment guideline for PC and novel clin-
ical trials for CRPC (4, 5), major challenges remain to un-
derstand and treat these cancers appropriately. Large-scale
-omics approaches, able to monitor cancer-induced changes
at the cellular level, are among the most promising strategies.
Proteomic strategies, by measuring the abundance and activ-
ity of proteins, have the ability to directly reflect the func-
tional activity of cells, and to point to deregulations in the
most druggable cellular components. In this context, several
proteomic studies started to map the landscape of the PC pro-
teome (6–10). These studies identified biomarkers, such as
the proneuropeptide Y 7, as well as proteomic changes asso-
ciated to prostate cancer progression (e.g., increased anabolic
processes and oxidative phosphorylation in primary prostate
cancer as described by (7) and (8)). Overall, such analyses
are valuable not only for diagnosis, but also for providing
mechanistic details related to disease etiology and progres-
sion.
These proteomic approaches focused on protein quantifica-
tion, but neglect protein phosphorylation, a key point in the
measurement of cellular activity. Protein phosphorylation
is a post-translational modification central to signal trans-
duction, that influences cell growth, division, differentiation,
cancer development and progression (11, 12). Protein phos-
phosites can trigger protein activation or inactivation, and
profiling the phosphorylation patterns of proteins can be a
powerful tool for understanding key roles in tumor progres-
sion and/or drug resistance (13). Technological advances in
the last decade have led to the development of several high-
throughput strategies to map the cellular phosphoproteome
(14). Several recent studies examined the phosphoproteome
of PC, thereby informing about the activity status of signaling
pathways involved in CRPC progression (15–17). In partic-
ular, a recent study integrating phosphoproteomics with tran-
scriptomics and genomics data revealed the diversity of ac-
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tivated signaling pathways in metastatic PC patients, in rela-
tion to their resistance to the anti-androgen therapy (18). This
work further demonstrated the utility of combining -omics
approaches to better understand PC and CRPC progression.
Here, we used a SILAC-based Mass Spectrometry approach,
and identified and quantified the proteomes and phosphopro-
teomes of four widely used prostate cell lines representative
of different cancerous and hormonal status. We first identi-
fied a common set of housekeeping proteins highly expressed
in all cell lines, and enriched in biological processes related
to RNA metabolism and oxidative stress. We further de-
tected that each cell line possesses specific protein, phospho-
site and functional features, in particular related to cellular
metabolism, transport and protein localization. In addition,
comparing the sensitive and resistant cell lines, we were able
to pinpoint potential biomarkers differentially expressed or
phosphorylated in the resistant context. Finally, pathway and
network-level interpretation of the biomarkers reveal cellular
processes associated with resistance, including, among oth-
ers, an upregulation of cell migration, extracellular processes
and epithelial-mesenchymal transition, and a downregulation
of the cellular respiration.
Methods
Cell culture and SILAC Labeling
We cultivated three replicates of four cell lines derived
from prostate tissue. PNT1A, a non-tumorigenic SV40-
immortalized human prostatic epithelial cell line (ECACC,
European Collection of Cell Cultures, England), castration-
sensitive (CS) LNCaP (ATCC, American Type Culture Col-
lection (Rockville, MD, USA)) as well as castration-resistant
(CR) DU145 and PC3 cell lines (ATCC). All cell lines were
routinely cultured at 37°C in a humidified 5% CO2-95% air
atmosphere. They were maintained in Dulbecco’s Modi-
fied Eagle’s Medium (PC3) and RPMI-1640 (Roswell Park
Memorial Institute) (Invitrogen, Cergy Pontoise, France),
supplemented with 10% fetal bovine serum (FBS). Stable
Isotope Labelling with Amino acids in Culture (SILAC) la-
beling of cell lines was carried out according to (19, 20)
using SILAC media with 10% dialyzed fetal bovine serum
supplemented with 13C6
15N2-L-lysine (K8) and
13C6
15N4-L-
arginine (R10). Before creating the reference proteome, the
incorporation rate of the heavy amino acid was checked for
each cell lines using LC-MS/MS and cell extracts were used
if this rate reached 95% (data not shown). Additionally, the
interconversion of arginine to proline was checked and found
to be negligible (data not shown). Cells were washed on ice
with PBS and collected in a lysis buffer containing 4% SDS,
100 mM Tris-HCl pH7.4, 1 mM DTT (with protease and
phosphatase inhibitors cocktails, EDTA-free, ROCHE, usu-
ally 1 tablet of each per 10 ml of lysis buffer). Each pellet was
resuspended in the lysis buffer and heated to 95°C for 5 min.
Viscous lysates were first homogenized mechanically with a
syringe and DNAse was added at a 1:40 dilution (benzonase
endonuclease, Sigma). Samples were left on ice for 40 min,
then centrifuged at 16000 rcf (g) for 25 min. Supernatants
were collected in clean Lo-Bind Eppendorf tubes and protein
quantitation was done using BCA assay. After cell lysis, the
protein extracts from the four heavy cell lines were mixed
in equimolar amounts (1:1:1:1), to generate the super SILAC
reference proteome which was then aliquoted and stored at
-80°C. For proteomics and phosphoproteomics profiling the
reference proteome was mixed in equimolar amounts with
protein extracts from each non-labeled cells (Figure 1, C).
Proteomes preparation
40 µg of protein extract were loaded on NuPAGE 4–12%
bis–Tris acrylamide gels (Life Technologies) to separate pro-
teins, and were stained with Imperial Blue (Pierce, Rockford,
IL). Each lane of the gel was cut into 20 bands that were
placed in individual Eppendorf tubes. Gel pieces were sub-
mitted to an in-gel trypsin digestion using a slightly modi-
fied version of the method described by (21). Briefly, gel
pieces were washed and destained using few steps of 100mM
ammonium bicarbonate. Destained gel pieces were shrunk
with 100 mM ammonium bicarbonate in 50% acetonitrile
and dried at RT. Protein spots were then rehydrated using
10mM DTT in 25 mM ammonium bicarbonate pH 8.0 for 45
min at 56°C. This solution was replaced by 55 mM iodoac-
etamide in 25 mM ammonium bicarbonate pH 8.0 and the
gel pieces were incubated for 30 min at room temperature
in the dark. They were then washed twice in 25 mM am-
monium bicarbonate and finally shrunk by incubation for 5
min with 25 mM ammonium bicarbonate in 50% acetoni-
trile. The resulting alkylated gel pieces were dried at RT. The
dried gel pieces were re-swollen by incubation in 25 mM am-
monium bicarbonate pH 8.0 supplemented with 12.5 ng/ml
trypsin (Promega) for 1h at 4°C and then incubated overnight
at 37°C. Peptides were harvested by collecting the initial di-
gestion solution and carrying out two extractions; first in 5%
formic acid and then in 5% formic acid in 60% acetonitrile.
Pooled extracts were dried down in a centrifugal vacuum sys-
tem.
Phosphoproteomes preparation
For each condition, 400 µg of cell lysate implemented with
400 µg of the reference proteome was precipitated using Ace-
tone/Ethanol (sample/Acetone/EtOH 1/4/4 v/v/v) overnight
at -20°C. The acetone-precipitated lysate was resolubilized in
50 mM ammonium bicarbonate, pH 8.0. The soluble proteins
were reduced for 45 min at 56°C with 10 mM dithiothreitol
(DTT), and then alkylated for 30 min at room temperature in
the dark with 10mg/ml Iodoacetamide. The protein mixture
was then digested with trypsin (1:50 w/w) overnight. Trypsin
was quenched by acidification of the reaction mixture with
TFA. The peptide mixture was desalted and concentrated on a
C18-SepPak cartridge (Waters, Milford, MA) and eluted with
1x 2 mL of 75% acetonitrile (ACN) in 0.1% TFA and dried
down. The phosphopeptide enrichment was performed with
TiO2 beads 10 µm (Titansphere TIO, GL Sciences, Japan).
Titania beads (6 mg) were prepacked in 200 µL pipet tips
filled at the orifice with a C8 Empore disk (3M Empore).
Prior to loading samples, the titania tips were rinsed with
200 µL of buffer A (3% TFA/70% CH3CN). Digest samples
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were reconstituted with 200 µL of loading buffer (buffer A +
1M Glycolic acid). After centrifugation the supernatant was
slowly loaded three times onto the titania tip using centrifu-
gation at 300 g for 10 min. The titania beads were sequen-
tially washed with 200 µL loading buffer, twice with 200 µL
of buffer A and 200 µL of 0.1% TFA. Bound peptides were
eluted with 140 µL of 1% NH4OH pH 10.5 and dried down
with a vacuum concentrator.
Mass Spectrometry analysis
Samples were reconstituted in 0.1% TFA 4% acetonitrile
and analyzed by liquid chromatography (LC)–tandem Mass
Spectrometry (MS/MS) using Q-Exactive Mass Spectrome-
ter (Thermo Electron, Bremen, Germany) for proteome and
phosphopeptide experiments. For the phosphopeptide exper-
iments, an LTQ-Orbitrap Velos Mass Spectrometer (Thermo
Electron, Bremen, Germany) was also used. Mass Spectrom-
eters were on line with a nanoLC Ultimate 3000 chromatog-
raphy system (Dionex, Sunnyvale, CA). Peptides were sep-
arated on a Dionex Acclaim PepMap RSLC C18 column at
37°C. First, peptides were concentrated and purified on a pre-
column from Dionex (C18 PepMap100, 2 cm x 100 µm I.D,
100Å pore size, 5 µm particle size) in solution A (0.05% tri-
fluoroacetic acid - 2% acetonitrile). In the second step, pep-
tides were separated on a reverse phase column from Dionex
(C18 PepMap100, 15 cm x 75 µm I.D, 100Å pore size, 2 µm
particle size) at 300 nL/min flow rate. After column equili-
bration by 4% of solution B (20% water – 80% acetonitrile
– 0.1% formic acid), peptides were eluted from the analyt-
ical column by a two steps linear gradient. For proteome
analyses, these two steps were 4-25% acetonitrile/H2O; 0.1%
formic acid for 40 min and 25-50% acetonitrile/H2O; 0.1%
formic acid for 10 min. For phosphopeptide analyses, these
two steps were 4-20% acetonitrile/H2O; 0.1% formic acid
for 90 min and 20-45% acetonitrile/H2O; 0.1% formic acid
for 30 min. For peptides ionisation in the nanospray source,
spray voltage was set at 1.5 kV and the capillary temperature
at 275°C. Instrument method for the Q-Exactive was set up
in data dependant mode to switch consistently between MS
and MS/MS. MS spectra were acquired with the Orbitrap in
the range of m/z 300-1700 at a FWHM resolution of 70000
(AGC target at 1e6, maximum IT 120 ms and 250 ms for
proteomes and phosphopeptides respectively). For internal
mass calibration the 445.120025 ions was used as lock mass.
The 12 most intense ions per survey scan (Intensity threshold
1e5) were selected for HCD fragmentation (AGC target 5e5,
NCE 25%, maximum IT 60 ms) and resulting fragments were
analysed at a resolution of 17500 in the Orbitrap. Charge
state screening was enabled to exclude precursors with unas-
signed, 1 and > 8 charge states. Fragmented precursor ions
were dynamically excluded for 25 s. For phosphopeptides
analysis using the LTQ-Orbitrap Velos, the Mass Spectrome-
ter was set as above except for the following parameters. Sur-
vey spectra were acquired with a resolution of 60000 (AGC
target at 1e6, maximum IT 100 ms) and the 15 most in-
tense precursors ions per cycle were selected for fragmen-
tation by activation of the neutral loss ions (-48.99, -32.66,
and -24.49 Thompson relative to the precursor ions) with
collision induced dissociation (AGC target 3000, NCE 35%,
maximum IT 200 ms). The Mass Spectrometry proteomics
data, including search result, have been deposited to the
ProteomeXchange Consortium (www.proteomexchange.org)
(22) via the PRIDE partner repository with datasets identi-
fiers PXD004970 and PXD004992.
Protein identification and quantification
Relative intensity-based SILAC quantification was processed
using MaxQuant computational proteomics platform, version
1.3.0.5 (23). First the acquired raw LC Orbitrap MS data
were processed using the integrated Andromeda search en-
gine (24). Spectra were searched against a SwissProt human
database (version 2014.02; 20284 entries). This database was
supplemented with a set of 245 frequently observed contam-
inants. The following parameters were used for searches: (i)
trypsin allowing cleavage before proline (25) ; two missed
cleavages were allowed; (ii) monoisotopic precursor toler-
ance of 20 ppm in the first search used for recalibration, fol-
lowed by 6 ppm for the main search and 20 ppm for frag-
ment ions from MS/MS; (iii) cysteine carbamidomethylation
(+57.02146 Da) as a fixed modification and methionine oxi-
dation (+15.99491 Da) and N-terminal acetylation (+42.0106
Da) as variable modifications; (iv) a maximum of five modifi-
cations per peptide allowed; and (v) minimum peptide length
was 7 amino acids. The re-quantify option was enabled to
search for missing SILAC partners. The quantification was
performed using a minimum ratio count of 2 (unique+razor)
and the second peptide option to allow identification of two
co-fragmented co-eluting peptides with similar masses. The
false discovery rate (FDR) at the peptide level and protein
level were set to 1% and determined by searching a reverse
database. For protein grouping, all proteins that cannot be
distinguished based on their identified peptides were assem-
bled into a single entry according to the MaxQuant rules.
Phosphopeptide identification and quantification
Peptide identification was done similarly than above using
MaxQuant software except that serine, threonine, and tyro-
sine phosphorylation (+79.96633 Da) were allowed as vari-
able modifications.
Preliminary treatment of the datasets
Statistical analyses were done with the Perseus program (ver-
sion 1.3.0.5; freely available at www.maxquant.org) from the
MaxQuant environment (26). The relative intensity-based
SILAC ratio, iBAQ normalised intensities and peptide inten-
sities were uploaded from the proteinGroups.txt and Phos-
pho(STY)Sites.txt files for proteome and phosphoproteome
studies, respectively. Proteins marked as contaminant, re-
verse hits, and “only identified by site” were discarded.
One DU145 cell line replicate in the phosphoproteome study
was discarded due to high divergence. In all other cases, for
each experiment and for each cell line, the measurements of
three replicates were considered. We identified 3219 proteins
(FDR 1% for peptide and protein identification) in triplicates
Katsogiannou et al. | Integrative proteomic and phosphoproteomic profiling of prostate cell lines bioRχiv | 3
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/696450doi: bioRxiv preprint first posted online Jul. 9, 2019; 
(Supplementary Table 1). We kept for further quantification
analyses only those proteins containing at least two valid val-
ues (over the 3 replicates) in each cell line. This very conser-
vative approach avoids imputing missing values, and ensures
the results of the statistical tests. Doing so, we quantified
1229 proteins (Supplementary Table 1), used for all subse-
quent analyses. For the phosphoproteomics analysis, a simi-
lar strategy allowed identifying 3746 phosphosites, of which
563 were kept for further quantification analysis following
the previously defined filters (Supplementary Table 2).
Data analyses
R statistical programming environment (27) was used for the
treatment of the proteomic and phosphoproteomic datasets.
Expression ratios towards the internal standard were base-2
logarithmized and normalized using z-scores.
Clustering
Unsupervised hierarchical clustering using average method
was performed for the proteomic and phosphoproteomic
datasets based on Euclidean distances of the expression ra-
tio after normalization.
Identification of the highly-expressed housekeeping pro-
teome
The abundance of each protein in each cell line was com-
puted as the sum of the IBAQ values of every replicate. The
housekeeping proteome was obtained by selecting the 10%
most abundant proteins matching across all cell lines.
Identification of differentially expressed proteins and phos-
phosites
We first applied a 1-way ANOVA over the four different cell
lines. Benjamini & Hochberg FDR (28) was used for multi-
ple testing corrections, and the threshold for significance was
set to 0.01.
Next, to characterize cell line specific protein/phosphosite
expression, a t-test was applied to compare the expression
value in the three PC cell lines (LNCaP, DU145 and PC3) to
the reference non-tumorigenic PNT1A cell line. Benjamini
& Hochberg FDR (28) was used for multiple testing correc-
tions, and the threshold of significance set to 0.1.
Pairwise comparisons of protein/phosphosite expression val-
ues between the castration-sensitive (CS: LNCaP) and the
castration-resistant cell lines (CR: DU145 and PC3) were
performed with a t-test, and the threshold of significance
set to 0.1 after FDR multiple testing corrections. The re-
sults of the pairwise comparisons with the two CR cell lines
were combined to define proteins/phosphosites always sig-
nificantly up- or downregulated in CS as compared to CR.
It is to note that these analyses are conducted with a very
stringent filter that select only proteins and phosphosites with
at least two over three valid quantification values in all four
cell lines. In this context, the proteins identified only in
the CR resistant or only in the CS sensitive contexts were
discarded, whereas they could be considered as pertinent
biomarkers. We then also rescued these potential biomark-
ers as "CR_only" proteins and phosphosites, having at least
two valid expression values in CR and strictly none in CS
cell lines and "CS_only" proteins and phosphosites, having
at least two valid values in the two CS cell line and strictly
none in the CR cell lines.
Pathway and biological process analyses
Functional Enrichments
Enrichment Analyses were conducted with G:Profiler (29),
and the significance threshold set to 0.01 after FDR multiple
testing corrections. The list of 1229 proteins used for quan-
tification analyses was used as statistical background. Addi-
tionally, the strong filter option was selected on G:Profiler to
display solely the most significant ontology in each ontolog-
ical group, and reduce annotation redundancy.
ROMA
ROMA (Representation and Quantification of Module Ac-
tivity) is a software focused on the quantification and repre-
sentation of biological module activity using expression data
(30). The reference gene sets used for this analysis were se-
lected from pathway databases including Reactome (31) and
HALLMARK (32). For each of these pathways, a score cor-
responding to the weighted sum of the protein expression was
computed. The weights are based on the first principal com-
ponent (PC1). ROMA quantifies the statistical significance of
the amount of variance explained by the PC1, and is referred
to as the gene set overdispersion. Overdispersed pathways
are selected based on a p-value set to 0.01, and the result-
ing list of pathways can be interpreted as the pathways that
contribute significantly to the total expression variance. A
detailed presentation of the computational method and use of
software can be found at (30). For this study, we applied
on the proteomic dataset an R implementation of ROMA
(https://github.com/Albluca/rRoma), which is an improved
version of the initial software. The results are presented as
a heatmap where the mean value of the scores was computed
by types of cancer cell lines: CS for castration-sensitive and
CR for castration-resistant, and scaled between -1 and 1.
Ingenuity Pathway Analysis (IPA)
Proteomic datasets were also analyzed with Inge-
nuity Pathway Analysis (IPA) software (Qiagen,
http://www.ingenuity.com/) to predict pathway activa-
tion or inhibition. The IPA knowledgebase, derived from
literature, compute a score based on one-tailed Fisher test.
The final score corresponds to the negative log of p-value,
and thresholds were set to 0.01.
KSEA
In order to use the KSEA App
(https://casecpb.shinyapps.io/ksea/) (33) on the phos-
phoproteomic datasets, we computed the fold-changes (FC)
between DU145 and LNCaP, and between PC3 and LNCaP,
using the mean raw expression values of the replicates. We
selected the sites where the expression values are over or
under-expressed in both CR cell lines in comparison with
LNCaP. Finally, we computed the mean of the FC for the
337 Sites, and normalized it between 0 and 1.
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We used this list of sites as input for the KSEA App. The
kinases with at least 3 targeted phosphosite substrates, and a
p-value smaller than 0.05 were considered as significant.
Network analyses
We constructed a network encompassing molecular com-
plex interaction data by merging Corum complexes (34) and
Hu.MAP complexes (35). This network contains 8653 nodes
and 91500 edges. Then, we fetched interactions between:
• Proteins significantly differentially expressed in CR
versus CS;
• Proteins containing phosphosites significantly differ-
entially expressed in CR versus CS;
• Proteins and proteins containing phosphosites iden-
tified only in CR or CS contexts (CR_only and
CS_only).
Overall, the interactions between these proteins led to an in-
teraction network of 359 nodes and 1161 edges, including
a large connected component encompassing 194 nodes and
1098 edges represented with Cytoscape (36). For visualiza-
tion purposes, the expression values mapped on the network
in Figure 4 correspond to the mean of the expression of PC3
and DU145 cell lines.
Results
Proteomic and phosphoproteomic profiles of prostate
cell lines
In order to elucidate prostate cancer progression and an-
drogen escape pathway with proteomics and phosphopro-
teomics identification and quantification, we selected four
widely exploited prostate cell lines, namely PNT1A, LNCaP,
DU145 and PC3 for proteomic and phosphoproteomic profil-
ing (Figure 1, A). These cell lines are routinely used, and are
representative of normal, cancerous and castration-resistant
progression of prostate cancer (Figure 1, B). The PNT1A
benign prostate cell line was established by immortalizing
non-tumorigenic human prostate benign epithelial cells by
transfection with the SV40 large-T antigen gene (37). The
castration-sensitive LNCaP cell line was established from
metastatic deposit in a lymph node and demonstrates an-
drogen sensitivity (38). Finally, the two castration-resistant
tumor cell lines, DU145 and PC3, were established from
metastatic deposits (bone/lumbar spine and central nervous
system, respectively), lack the androgen receptor (AR) and
are androgen-independent. Moreover, PC3 cells are more tu-
morigenic and have a higher metastatic potential than DU145
(39). It is to note that the benign PNT1A cell line also
lacks the AR. The loss of AR and prostate-associated markers
(PSA and PAP) appears to be a consistent feature of immor-
talized cells of prostatic origin, observed in SV40 immortal-
ized cell lines such as PNT1A (40).
We used Stable Isotope Labelling with Amino acids in Cul-
ture (SILAC) and Mass Spectrometry (MS) to identify and
quantify the proteomes of these four cell lines (41, 42) (Fig-
ure 1, C, Methods). We elected the spike-in super SILAC
method described by (19, 20). In this protocol, the protein ex-
pression in each cell line is compared to the same reference
proteome, thereby maximizing the number of detected pro-
teins. We identified 3219 proteins (Supplementary Table 1).
We plotted the median iBAQ values considering all the cell
lines to estimate the absolute abundance of the 3219 identi-
fied proteins, and obtained the expected S-shaped distribution
covering six orders of dynamic range of MS signals (Meth-
ods, Supplementary Figure 1). The most highly expressed
proteins include the core histones, tubulins as well as heat
shock proteins. Both the most abundant proteins detected as
well as the lowest ones have been previously reported in other
studies with a similar approach (43). We kept for further anal-
ysis only those proteins containing at least two valid quantifi-
cation values over the 3 replicates in each cell line. This very
conservative approach avoids imputing missing values, and
ensures the results of the statistical tests. Doing so, we used
for subsequent analyses the quantitative expression data of
1229 proteins (Supplementary Table 1).
A similar strategy was used to identify and quantify phos-
phopeptides (Methods). We identified 3746 phosphosites, of
which 563 were kept for expression analysis considering the
strong filters we defined (Supplementary Table 2). These
563 phosphosites correspond to 381 proteins. Overall, 135
proteins were associated with quantitative expression values
both at the proteomic and phosphoproteomic levels, with a
correlation ranging from 0.43 to 0.62 in each of the four cell
lines (Supplementary Figure 2). Therefore, the level of phos-
phorylation of a protein is not strictly correlated to its level
of expression, but might also reflect its activity status.
The unsupervised clustering of the quantified proteins and
phosphosites first confirms that the cell line replicates clus-
ter together (Figure 1, D and E). In addition, we observed
that the benign PNT1A cell line clusters with the resistant
DU145. The genetic instability associated with continuous
propagation in culture is a particular problem with benign im-
mortalized cell lines such as PNT1A, in which the insertion
of viral DNA drives the cell to replicate continuously (44).
This might explain why its global expression patterns may be
similar to that of more malignant cell lines.
The highly-expressed housekeeping proteome
A large number of proteins are essential in all the cells, sug-
gesting that their expression is crucial for the maintenance of
basic functionality and survival (45). These proteins are of-
ten called housekeeping. We focused here on the top 10%
most expressed proteins in each cell line, corresponding to
321 proteins. Among those 321 highly expressed proteins,
257 are common to the four cell lines (Methods, Supplemen-
tary Table 3). This means that 80% of the most expressed
proteins are the same in all the four cell lines studied here,
and can thereby be defined as the highly-expressed house-
keeping proteome.
This housekeeping proteome is enriched in functions related
to RNA metabolism and response to oxidative stress (func-
tional enrichments with G:Profiler (29), Methods and Supple-
mentary Table 5). It contains for instance many RNA binding
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Fig. 1. Overall overview of our study. (A) Prostate cell lines used in the present
study. AR: Androgen Receptor. (B) Prostate Cancer (PCa) progression over time,
from localized asymptomatic castration-sensitive to metastatic castration-resistant
disease. (C) SILAC Cell line culture preparation, Spike-in and Mass Spectrometry
analysis of the proteomes and phosphoproteomes. Figure adapted from (19) (D)
Hierarchical clustering of the proteomes and (E) phosphoproteomes normalized
expression data in the four cell lines.
proteins (mainly from the RPS family) and structural con-
stituents of the ribosome. Eight members of the eukaryotic
chaperonin TriC/CCT complex are also highly abundant in
all the four cell lines studied.
LNCaP, DU145 and PC3 cancer cell lines characteriza-
tion
In a second step, we focused on the differences between the
cell lines. We first conducted an ANOVA analysis to identify
the proteins and phosphosites with the most variation among
the four cell lines (Methods). 46 proteins and 13 phospho-
sites (corresponding to 13 proteins) are varying significantly
among the four cell lines (FDR < 0.01, Supplementary Ta-
bles 3 and 4). Almost half of the 46 ANOVA-significant pro-
teins play a role in stress response (e.g., DNAJB1, VDAC1,
ZYX, TCEB1), several are involved in actin cytoskeleton or-
ganization (e.g., ACTN1, RHOA, PLS3), and 15 proteins are
associated with RNA binding (e.g., CCT6A, NOP2, OCT3,
HNRNPA2B1). Among the 13 proteins with phosphosites
associated with ANOVA-significant variations in the four cell
lines, five are cell-adhesion molecule binding (SEPT9, AH-
NAK, TNKS1BP1, SCRIB, TAGLN2). Of note, Septin-9
(SEPT9), a filament-forming cytoskeletal GTPase, presents
significant variations across the cell lines both at the protein
and Serine-30 phosphosite levels (Supplementary Figure 3).
SEPT9 has been shown to be highly expressed in PC and pos-
itively correlates with malignant progression (46).
Interestingly, two highly expressed housekeeping proteins
are associated with phosphosites differentially expressed be-
tween the four cell lines according to the ANOVA analysis.
First, TAGLN2 presents a significant variation in the Serine-
163 expression. In liver cancer, this protein has been re-
ported as a putative tumor suppressor and the involvement
of its phosphorylation in actin binding and cell migration has
been demonstrated (47). Second, HNRNPA1, involved in the
packaging of pre-mRNA, is highly expressed in the four cell
lines, but also shows significant differential phosphorylation
levels in the Serine-6. To our knowledge, a role for HN-
RNPA1 phosphorylation in PC has not been described pre-
viously.
In order to provide insights into the cellular mechanisms that
are involved in cell malignant transformation, we then com-
pared protein and phosphosite levels in each of the three can-
cer cell lines (LNCaP, DU145 and PC3) to the benign PNT1A
cell line (Methods). On a global scale, LNCaP clusters apart
and appears to be the most divergent cell line (Figure 1, D).
LNCaP cells display 226 up- and 219 downregulated proteins
as compared to PNT1A (Supplementary Table 3). Functional
enrichment analyses reveal that the proteins upregulated in
LNCaP are related to cellular metabolism (Figure 2, A, Sup-
plementary Table 5). The association of tumorigenesis and
metabolism is well established; it is not surprising that a can-
cer cell, in order to meet its increased requirements of pro-
liferation, displays fundamental changes in pathways of en-
ergy metabolism and nutrient uptake (48). In contrast, the
proteins downregulated in LNCaP as compared to PNT1A
are enriched in cell recognition and protein/RNA localization
processes. Protein and RNA localization mechanisms have
shown to play pivotal roles for the presence of specific pro-
tein components in cancer cell protrusions, involved in cell
migration and invasion (49). Cell recognition is one of the
ways that cells communicate with each other and their envi-
ronment (adhesion proteins, surface molecules); loss of cell
recognition has been shown to lead to cancer development
(50). IPA analysis (Methods) confirmed a high metabolic ac-
tivity in LNCaP, in particular an upregulation of TCA cycle
for aerobic respiration. It further delineates a downregula-
tion in the RAN signaling pathway, central to the nucleo-
cytoplasmic transport, with seven downregulated proteins, in-
cluding RAN and its regulator RANBP1, four importins and
one exportin (Supplementary Table 5).
The resistant cell line DU145 presents 80 up- and 92 down-
regulated proteins as compared to PNT1A. Upregulated pro-
teins are enriched in transport and cellular organization pro-
cesses. Moreover, 61/80 proteins upregulated in DU145
are annotated as extracellular proteins. By contrast, we ob-
served that proteins downregulated in DU145 as compared to
PNT1A are enriched in cellular respiration and protein/RNA
localization (Figure 2, B, Supplementary Table 5). IPA analy-
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sis confirmed an upregulation of actin and Rho signaling and
a downregulation of TCA cycle for aerobic respiration.
Finally, the most tumorigenic cell line, PC3, displays 180
up- and 158 downregulated proteins as compared to PNT1A.
The upregulated proteins are enriched in vesicle-mediated
transport, as it is the case for the other resistant cell line
DU145 (Figure 2, C, Supplementary Table 5). In recent
years, several publications have proposed vesicle-mediated
transport as a mechanism to explain the transfer of resistance
to drugs among tumorigenic cells (51). In addition, many
proteins upregulated in PC3 are localized in the extracellu-
lar exosome. The proteins downregulated in PC3 are en-
riched in toxin transport and protein-RNA localization pro-
cesses. These functional enrichments are complemented by
the IPA analysis that revealed strong enrichment in epithelial
adherence junction annotation among the upregulated pro-
teins in PC3. Overall, we identified 13 proteins upregulated
and 19 proteins downregulated together in LNCaP, DU145
and PC3 cells as compared to PNT1A (Supplementary Ta-
ble 3). We propose that these proteins, differentially ex-
pressed in the PC cell lines as compared to the benign cell
line, could constitute markers of oncogenic transformation.
The upregulated proteins are almost all annotated for secre-
tion and exosomes (e.g., RAB5B, RAB7A, RPL36A, NES,
SRI). It has been recently described that exosomes derived
from PC cells modulate the prostatic tumor adjacent envi-
ronment by inducing, among others, tumor-associated target
cells growth (52). Among the 19 downregulated proteins,
several are annotated for regulation of protein stability and
chaperone-mediated protein folding, and almost half are in-
volved in DNA metabolism. Overall, many proteins of the
chaperonin TriC/CCT folding complex, which were observed
as highly abundant in all cell lines and thereby classified
as housekeeping, are also underexpressed in the three can-
cer cell lines as compared to PNT1A. The TriC/CCT chap-
eronin complex directly modulates the folding and activity
of as many as 10% of cytosolic client proteins (53, 54). Re-
cently, the TRiC/CCT complex was also shown to be required
for maintaining the wild-type conformation of the tumor sup-
pressor p53 (55). The downregulation of this chaperone com-
plex could promote the oncogenic functions of p53, such as
cancer cell migration and invasion.
We reproduced the cell line characterization protocol for
phosphosites, thereby identifying 146 up- and 98 downreg-
ulated phosphosites in LNCaP, 5 up- and 3 down in DU145,
and 82 up- and 44 down in PC3, as compared to PNT1A.
No functional enrichments were significant for the corre-
sponding proteins. Nevertheless, two proteins are associ-
ated with phosphosites significantly deregulated in all three
PC cell lines as compared to PNT1A. First, TP53BP1 (tu-
mor protein p53 binding protein 1) phosphosites Serine-500
and Threonine-1056 are downregulated in LNCaP. TP53BP1
Serine-500 phosphosite is also downregulated in DU145, and
the Threonine-1056 phosphosite downregulated in PC3, as
compared to PNT1A. This TP53BP1 protein is well known
to be involved in DNA Damage Response (DDR) and its
phosphorylation could be a marker of malignant transforma-
tion (56). Previously published studies described TP53BP1
phosphorylation necessary for recruitment to DNA double
strand breaks (DSB) (57). In this context, a downregulation
of TP53BP1 phosphorylation, as we observed in the three PC
cell lines, could lead to impaired DDR. Second, the DEAD-
box RNA helicase 10 (DDX10) Serine-539 phosphosite is
significantly upregulated in LNCaP, DU145 and PC3 as com-
pared to PNT1A. DDX10 is an ATP-dependent RNA helicase
(58), but, to our knowledge, little is known about its phos-
phorylation and function in cancer. Other members of the
same family of RNA helicases have been well described, and
the phosphorylation of DDX p68 is reported to be associated
with cancer development and cell proliferation (59). Interest-
ingly, the phosphosite Serine-539 that we identified as upreg-
ulated in PC cell lines is one of the known post-translational
DDX modification sites (60). Thus, our approach allowed us
identifying a well-known cancer-related phosphosite, as well
as another potential new candidate.
Fig. 2. Functional Enrichments of proteins up- and downregulated in PC cell
lines. Bar graphs represent relative fold change of Gene Ontology Biological Pro-
cesses among (A) LNCaP, (B) DU145, (C) PC3 upregulated proteins (red bars) and
downregulated proteins (green bars), as compared to PNT1A cells. Significance is
represented in the dot plot by –log (P-values).
Identification of Resistance markers
One of the features of PC is, in most cases, its progression
to highly aggressive and incurable castration resistant (CR)
disease after androgen deprivation therapy. Identifying resis-
tance biomarkers is essential to guide the development of new
therapeutic strategies and avoid drug resistance. In order to
identify proteins and processes potentially involved in resis-
tance, we compared the protein expression levels in LNCaP
cell line (castration-sensitive, CS) with DU145 and PC3, the
two castration-resistant cell lines (CR). We found 135 pro-
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teins upregulated and 135 downregulated in CR as compared
to CS cell lines, and propose them as resistance biomarkers
(Supplementary Table 3). Protein biomarkers upregulated in
the CR contexts are functionally enriched in processes related
to cell-cell adhesion and external communication (Figure 3,
A, Supplementary Table 5). This finding is in accordance
with previously published studies demonstrating the involve-
ment of these processes in invasion and metastasis, features
for which CR cells have a higher potential (61). Conversely,
proteins downregulated in CR are enriched in cellular respi-
ration and protein maturation processes. The downregulation
of cellular respiration in the CR context could highlight the
Warburg effect (62), in which castration-resistant progression
would be associated with a switch from oxidative respiration
to glycolysis as primary energy source. The ROMA pathway
analysis tool (30) also points to a downregulation in CR cells
of oxidative phosphorylation and metabolic pathways such as
fatty acid metabolism, as well as signaling pathways related
to p53 and apoptosis (Figure 3, B). Conversely, it reveals an
upregulation of the epithelial-mesenchymal transition (EMT)
and reactive oxygen species (ROS) pathways. EMT refers to
the morphological and functional alterations involved in can-
cer invasion (63). Finally, IPA analysis points to an upregula-
tion of actin cytoskeleton and Rho signaling in CR cells, and
further identifies an upregulation of Integrin Signaling and
Calpain protease signaling.
Phosphoproteomics data reveal 41 phosphosites upregulated
and 40 downregulated in CR versus CS, which we also pre-
dict as resistance biomarkers (Supplementary Table 4). The
41 upregulated phosphosites concern essentially nuclear pro-
teins involved in functions such as transcription regulation,
genome stability and RNA processing (e.g., SMARCC1,
SRRM1, SRRM2, SSB). The deregulation of these processes,
and their implication in cancer development and progres-
sion, have been largely documented (64). Moreover, 2 ki-
nases are hyper-phosphorylated in the resistant context. First,
the Serine/threonine-protein kinase N2 (PKN2), which plays
a role in the regulation of cell cycle progression, actin cy-
toskeleton assembly, cell migration, cell adhesion, tumor cell
invasion and transcription activation signaling processes. It
was recently shown to be phosphorylated by the PI-3 Ki-
nase pathway and implicated in prostate cancer progression
(65). Second, the nuclear receptor binding protein (NRBP1),
which is involved in subcellular ER-Golgi trafficking. To our
knowledge, a role of its phosphorylation status in prostate
cancer has not been described previously.
The 40 downregulated phosphosites concern mainly pro-
teins involved in cell migration and invasion, such as
PLEC, AHNAK, ESYT1 and ZYX. A group of ki-
nases sharing the same identified peptide and that conse-
quently cannot be distinguished with the MS experiment
(CDK2;CDK3;CDK1;CDC2) shows a decrease in phospho-
rylation activity in the CR context.
Kinase-Substrate Enrichment Analysis (KSEA (33), Meth-
ods) predicted the high activity of 3 kinases, namely CDK1,
MAPK13 and MAPK3, with 9, 4 and 3 targeted phosphosites
that present significant changes in the CR context, respec-
tively (Supplementary Table 4). For instance, the Serine-25
and Serine-38 of the stathmin protein (STMN1) are targets
of the three kinases. The STMN1 protein displays a com-
plex pattern of activity and phosphorylation in cancers (66).
The sequestosome 1 protein (SQSTM1) Threonine-269 and
Serine-272 are targets of both CDK1 and MAPK13.
Another interesting set of putative biomarkers can be derived
from the proteins and phosphosites that have been identified
in the MS experiment, but that were not further considered for
quantification analyses because of the strong filtering criteria
we have defined. We thus rescued the proteins and phos-
phosites that have been identified in at least 2 replicates in
the CS cell line but that are completely absents in the CR
cell lines, and vice-versa (Methods). This concerns 140 pro-
teins and 5 phosphosites that are identified only in the CR cell
lines, and 8 proteins and 108 phosphosites that are identified
only in the CS cell line. Focusing particularly on kinases,
8 of them are identified only in the CR cell lines (CALM1,
EGFR, EIF2AK2, EPHA2, HK2, PIK3R4, PPP4C, ROCK2).
A majority of these kinases are involved in response to stress.
Two other kinases are associated with phosphosites identi-
fied only in the CR contexts (PRPF4B, TAOK1). TAOK1 is
particularly appealing as it activates the Hippo pathway in-
volved in cellular homeostasis (67). Finally, it is to note that
some phosphosites associated to significantly different lev-
els of phosphorylation are found in proteins that are quanti-
fied by our approach, and not differentially expressed in the
ANOVA. These might represent functionally relevant candi-
dates. These include 12 proteins (DKC1, BCLAF1, SRRM2,
NAP1L4, CLNS1A, TJP1, API5, SSB, SQSTM1, DHCR7,
NCBP1).
Proteome and phosphoproteome integration in a
molecular network
We finally sought to provide a larger-scale functional in-
terpretation of resistance-associated candidate biomarkers.
The separated analysis of the proteomics and phosphopro-
teomics datasets provided one-dimensional views of cellu-
lar processes. We expect to obtain a comprehensive per-
spective of cellular processes and their interplays by integrat-
ing the information about protein abundances, activation sta-
tus and molecular interactions (68, 69). Toward this goal,
we devised a network-guided integration of CS and CRPC
cell lines proteome and phosphoproteome, by mapping the
candidate biomarkers to molecular complex interaction data
(Methods). The resulting network is composed of 356 nodes
and 1161 edges, including a large connected component en-
compassing 194 nodes and 1098 edges (Figure 4). The net-
work reveals the links between up- and downregulated pro-
teins, up- and downregulated phosphosites and correspond-
ing proteins, as well as the links between the proteins and
phosphosites that were identified by the MS approach only
in the CR or CS contexts. At-a-glance, we can observe that
the network is organized around several strongly connected
subnetworks.
First, we identified a cell migration/invasion subnetwork,
which is composed mainly of upregulated proteins in CR
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Fig. 3. Functional Enrichments of protein resistance biomarkers. (A) Bar
graphs represent relative fold change of Gene Ontology Biological Processes
among proteins upregulated (red bars) and downregulated (green bars) in Castra-
tion Resistant cell lines DU145 and PC3 as compared to castration-sensitive LNCaP
cell line. Significance is represented in the dot plot by –log (P-values). (B) Clustered
heatmap of ROMA pathway analysis. The color intensities correspond to the values
of the scores of each signaling pathway (red, upregulated; green, downregulated).
cells (e.g., ANXA2, IQGAP1, ACTN4, TWF1, MYO1B,
CORO1C, ARPC4) (Figure 4). It contains in particu-
lar the plectrin protein (PLEC), overexpressed and hyper-
phosphorylated in CR; this protein is known to interlink cy-
toskeleton elements and promote cancer cell invasion and
migration (70). Indeed, it was shown that along with vi-
mentin intermediate filaments, plectrin provide a scaffold
for invadopodia formation, facilitating cancer cell invasion
extravasation for metastasis (71). Recently, (72) demon-
strated that upregulation of vimentin and plectrin expres-
sions positively correlates with the invasion and metastasis
of androgen-independent PC cells. Another interesting mem-
ber of this complex is ACTG1 (actin gamma-1), which is not
identified, and thereby might be not expressed, in CS cells.
ACTG1 is involved in cell motility/cytoskeleton maintenance
and cancer cell migration. ACTG1 was shown to induce
cancer cell migration in lung cancer cells and hepatocellu-
lar carcinoma cells (73). To date, there is no report concern-
ing ACTG1 involvement in PC. The subnetwork also con-
tains components of the Arp2/3 complex (ARPC1B, ARPC3,
ARPC4) involved in the regulation of actin polymerization.
A smaller subnetwork, composed of interactions between
EZR, MSN, SLC9A3R1 and EGFR, is located close to
the larger migration subnetwork. Ezrin (EZR) and moesin
(MSN) are scaffolding proteins that are involved in crosslink-
ing cytoskeletal and membrane proteins. Ezrin is involved in
oncogenesis through these interactions (74), and it was also
shown recently that Ezrin can increase the oncogenic func-
tions of EGFR (75). SLC9A3R1 is also a scaffold protein
that connects plasma membrane proteins with members of
the ezrin/moesin/radixin family linking them to the actin cy-
toskeleton and regulating their surface expression (76).
We also identified a small subnetwork of interacting pro-
teins involved in actin cytoskeleton regulation (e.g., STMN1,
CDC42, CRLK1). Intriguingly, we found that stathmin1
(STMN1) was both hyper- and hypo-phosphorylated in CR
cells. This protein is associated with cancer metastasis and
exhibits a complicated phosphorylation pattern in response
to various extracellular signals (77).
We next focused on a small subnetwork composed of pro-
teins underexpressed in the CR context. It contains prohibitin
(PHB), a putative tumor suppressor protein involved in the in-
hibition of DNA synthesis and regulating proliferation, and
prohibitin-2 (PHB2), a mediator of transcriptional repres-
sion by nuclear receptors, also potentially involved in mito-
chondrial respiration. Indeed, the subnetwork also contains
the VDAC1 mitochondrial membrane and plasma membrane
channel, involved in apoptosis. The role of this subnetwork
is unclear, but the proteins are depicted as members of the
same complexes in the Hu.map dataset (35). The subnetwork
is tightly linked to another subnetwork containing many mi-
tochondrial membrane ATP synthase proteins (e.g., ATP5F1,
ATP5B, ATP5H), also downregulated in CR cell lines.
A heterogeneous subnetwork is composed of many proteins
involved in splicing and RNA processing, that are either up-
or downregulated in CR cells (Figure 4). Splicing events con-
trol gene expression and their alterations have been shown
to play a role in cancer (78) and specifically in PC (79).
Fine regulation of expression and/or phosphorylation status
determines whether a splicing factor functions as a splic-
ing repressor or activator (80, 81). The subnetwork contains
the hypo-phosphorylated splicing factors SRRM1 (a highly
phosphorylated protein under normal conditions (82)) and
SRRM2. It also contains NCBP1, which is identified as
hyper-phosphorylated, and PRPF4B kinase and SPEN that
were both hypo-phosphorylated. The subnetwork also incor-
porates pre-mRNA splicing factor SYF2, absent in CR cells,
and SF3A1, TRAP1 and HSPD1 proteins that are downregu-
lated in CR cells. The protein phosphatase 1 (PPP1CA) is
contrarily upregulated. Interestingly, we can also observe
many proteins identified in the CR cell lines and absent in the
CS cell line, all involved in RNA processing and splicing (IK,
ZNF207, CTNNBL1, CRNKL1, SF3B4, HTATSF1, PHF5A,
PPP1R10). PPP1R10, the Ser/Thr-protein phosphatase-1
regulatory subunit 10 is only expressed in CR cells and is
absent in CS cells. It has been shown that certain Ser/Thr-
specific protein phosphatases are required for catalytic steps
of pre-mRNA splicing (83).
We then emphasize a large and highly connected component
(Figure 4) composed of proteins implicated in DNA damage
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response. It contains protein biomarkers downregulated in
CR cells (NPM1, NOLC1, RPL22L1, FBL, G3BP2), but also
several proteins identified only in the CR cell lines, namely
H2AFX, kinase CALM1, DDX47, UTP20, USP10, BYSL.
All these proteins interact with single-strand DNA-binding
protein and are involved in DNA repair and genome stability
(84). DNA repair and DNA damage response are known to
be defective in PC and lead to genome instability (85). In-
terestingly, several of the proteins of this subnetwork (e.g.,
UTP20, BYSL, RPL22L1, NOLC1) are known for their role
in RNA processing. There is an increasing number of stud-
ies demonstrating the involvement of RNA processing factors
in DNA damage response (86, 87). For instance, NOLC1
(nuclear and coiled-body phosphoprotein-1) is a regulator of
RNA polymerase I and has been recently shown to regulate
the nucleolar retention of TERF2, inducing telomeric DNA
damage (88).
A closer look into this molecular network allowed us to
pinpoint several interesting smaller subnetworks. For in-
stance, we noticed a small subnetwork composed of inter-
acting proteins RELA, IKBKAP, GLG1, KPNA3, KPNA4.
Importin subunits alpha-4 (KPNA3) and alpha-3 (KPNA4)
are involved in nuclear transport of NF kappa B (89), and
an elevated activity of the NF-kappa B signaling in CRPC
is positively correlated with poor prognosis in CRPC (90).
Close to this subnetwork, GATAD2B is known to form a
homodimer with GATAD2A and the complex is part of a
highly conserved chromatin-remodeling complex, the NuRD
complex associated with DNA damage-induced transcrip-
tion repression but also metastasis and EMT (91, 92). This
subnetwork is also linked to the SWI/SNF complex subunit
SMARCC1, which contains downregulated phosphosites in
PC3 and DU145 cells. SMARCC1 positively regulates tran-
scription and was previously shown to induce PC survival
(93). It interacts with proteins associated with phosphosites
only detected in CS cells (transcriptional elongation factor
TRIM28, transcription kinase BAZ1B and TOP2B), as well
as with proteins only identified in PC3 and DU145 cells (e.g.,
GATAD2B, GTF2F1), all involved directly or indirectly in
transcription regulation. The transcriptional reprogramming
in PC progression has been extensively studied, as it is one of
the hallmarks of CRPC (3, 94–96).
Discussion
We here generated and explored a SILAC proteomics and
phosphoproteomics dataset of prostate cell lines. We selected
the PNT1A, LNCaP, DU145 and PC3 cell lines first because
they are frequently used in prostate cancer research (97, 98),
and molecular profiling and comparisons would thereby be
highly valuable for researchers using them in routine. In ad-
dition, the elected cell lines are representative of normal, can-
cerous and castration-resistant prostate tissue, and therefore
reflect progression of the disease.
We decided to monitor proteome and phosphoproteome
jointly as they can give a complementary picture of the
molecular dynamics of the cells. Phosphoproteome char-
acterization provides insights into proteins’ phosphorylation
levels, which are not strictly correlated to proteins level of ex-
pression, but also reflect protein activity status (99). Molec-
ular characterization at these two levels of information is a
clear advantage in our study. We identified 3 219 proteins
at 1% FDR, and after several filtering steps, we performed
subsequent functional explorations on 1229 proteins. We
elected this conservative approach in order to avoid impu-
tation of missing values and ensure the results of the statis-
tical analyses. On the phosphoproteomics side, we identi-
fied 3746 phosphosites among which 563 are used for sub-
sequent analyses. We explored the proteins and phospho-
sites associated to the four PC cell lines; these profiles and
associated cellular processes could be related to underlying
biology of the cell lines (Figure 1, Supplementary Tables
1-3, Supplementary Figure 1). We further compared pro-
tein and phosphosite levels in each of the three cancer cell
lines (LNCaP, DU145 and PC3) to the benign PNT1A cell
line (Figure 2, Supplementary Tables 3-5). Doing so, we
proposed several candidates that could constitute markers of
oncogenic transformation. Notably, two proteins are associ-
ated with phosphosites significantly deregulated in all three
PC cell lines as compared to PNT1A: TP53BP1, well-known
cancer-related phosphosites downregulated in all three PC
cell lines and DDX10, a potential new candidate, upregu-
lated in PCa cell lines. We also highlighted differentially
expressed proteins and processes potentially involved in re-
sistance, by comparing the sensitive LNCaP cell line to the
two resistant DU145 and PC3 cell lines (Figure 3). Interest-
ingly, we identified 12 proteins associated to significant dif-
ferential phosphorylation but not different protein levels, in-
cluding several RNA binding proteins, sequestosome-1 pro-
tein (involved in autophagy in relation to many crucial sig-
nalling pathways), as well as DHCR7, an enzyme involved
in cholesterol metabolism, and TJP1, a tight junction pro-
tein. Finally, we proposed an integrated mapping of protein
abundances, activation status and molecular interactions, to-
wards functional interpretation of resistance-associated can-
didate biomarkers (Figure 4). We observed that the network
is organized around several strongly connected subnetworks
(cell migration/invasion subnetwork, actin cytoskeleton reg-
ulation, DNA synthesis and regulating proliferation, splicing
and RNA processing, DNA damage response) and several in-
teresting smaller subnetworks (transcription regulation, nu-
clear transport). Several of these proteins and phosphosites
are already related to cancer resistance in general, and some
specifically to PCa. Overall, this analysis represents a valu-
able resource that could be used as a starting point for further
hypothesis and experimental investigations.
Conclusion
The complex nature of PC, due to its clinical and molecu-
lar heterogeneities, makes it difficult to determine a perfect
model representing tumor development, and precludes easy
correlation of carcinoma cell lines with specific stages of PC.
Nevertheless, PC cell lines routinely used for the last three
decades have provided valuable resources for understanding
important functional molecular mechanisms involved in this
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disease. In the present study, we used four cell lines that con-
stitute a gold standard for pre-clinical studies of PC progres-
sion. We conducted a large SILAC-based Mass Spectrom-
etry identification and quantification of peptides and phos-
phopeptides of prostate benign, castration-sensitive (CS) and
castration-resistant (CR) cells, and characterized housekeep-
ing, cell line, cancer and resistance associated proteomes and
phosphoproteomes.
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